Q: Your work in discovering the role of cholesterol crystals on cardiovascular attacks is renowned. Could you tell us about the impact that this made on how we view and treat plaque?

Article By:

GEORGE S. ABELA, MD, MSc, MBA

Professor and Chief, Division of Cardiology
Michigan State University
East Lansing, MI

0
No votes yet

The inaugural Donald Fredrickson Conference on Familial Lipoprotein Disorders was convened on Sunday, April 29, 2018 at the end of the National Lipid Association Annual Scientific Sessions in Las Vegas. The meeting was chaired by Dr. Virgil Brown.

Article By:

P. BARTON DUELL, MD, FNLA

Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR

W. VIRGIL BROWN, MD, FNLA

Charles Howard Candler Professor of Internal Medicine Emeritus
School of Medicine
Emory University
Atlanta, GA
Diplomate, American Board of Clinical Lipidology

0
No votes yet

The Midwest Lipid Association is 510 members strong and represents Indiana, Illinois, Wisconsin, Michigan, Ohio, Kansas, Iowa, Missouri, North Dakota, South Dakota, Minnesota and Nebraska. We are pleased to have David R. Neff, DO, FNLA, serving as our President this year. We have an active and diverse group and Sanford A. Carimi, MD, FNLA, our Immediate Past President, took time at our February meeting to acknowledge the great MWLA representation on national level projects. Ann M.

Article By:

SARAH J. HALLBERG, DO, MS, FNLA

President-Elect, Midwest Lipid Association
Medical Director
Medically Supervised Weight Loss Program
Indiana University Health Arnett
Indiana University School of Medicine
Lafayette, IN
Diplomate, American Board of Clinical Lipidology

0
No votes yet

Background

Article By:

GEORGE S. ABELA, MD, MSc, MBA

Professor and Chief, Division of Cardiology
Michigan State University
East Lansing, MI

0
No votes yet

Volanesorsen is a novel pharmacotherapy designed to treat patients with Familial Chylomicronemia Syndrome (FCS). This is a highly comorbid disease without any currently available pharmacotherapies to help reduce triglycerides or the more feared complication, pancreatitis. This has left a void in treatment that volanesorsen has attempted to address.

Article By:

DAVID J. DAVIDSON, MD

Clinical Educator
NorthShore Medical Group
Chicago, IL
Diplomate, American Board of Clinical Lipidology

0
No votes yet

COMMITTEE NOTE TO MEMBERS OF THE NATIONAL LIPID ASSOCIATION: At the request of the NLA President, the NLA Board of Directors, the Science and Policy Council, the Practice Management Council and the Health Quality and Research Committee, it is with pleasure that the 2017-18 NLA Therapeutics Committee presents a Special Report on how to best incorporate PCSK9 Inhibitors into routine clinical lipid practice by integrating best available evidence into the routine process of care.

Article By:

DEAN A. BRAMLET, MD, FNLA

2017-18 Co-Chair, NLA Therapeutics Committee
Assistant Consulting Professor of Medicine
Duke University
Medical Director, Cardiovascular Diagnostic Center
The Heart & Lipid Institute of Florida
St. Petersburg, FL
Diplomate, American Board of Clinical Lipidology

DAVID R. NEFF, DO

2017-18 Co-Chair, NLA Therapeutics Committee
President, Midwest Lipid Association

Michigan State University
College of Osteopathic Medicine
Associate Clinical Professor
Department of Family & Community Medicine
Ingham Regional Medical Center
Lansing, MI

DEAN G. KARALIS, MD, FNLA

Clinical Professor of Medicine
Jefferson University Hospital
Philadelphia, PA
Diplomate, American Board of Clinical Lipidology

 

PAUL E. ZIAJKA, MD, PhD, FNLA

Director
Florida Lipid Institute
Winter Park, FL
Diplomate, American Board of Clinical Lipidology

0
No votes yet

Lipodystrophies are a group of disorders of fat tissue loss that are classified according to whether the condition is genetic or acquired and by the distribution of fat loss, either generalized or partial (Table 1).1 Generalized lipodystrophy is a rare, complex, and clinically heterogeneous disorder characterized by the widespread loss of adipose tissue.

Article By:

JONATHAN Q. PURNELL, MD

Professor of Medicine, Division of Cardiovascular Medicine School of Medicine
Graduate Programs in Human Nutrition School of Medicine
Oregon Health & Science University
Portland, OR

ELIOT A. BRINTON, MD, FNLA

President, Utah Lipid Center
Salt Lake City, UT
Diplomate, American Board of Clinical Lipidology

SERGIO FAZIO, MD, PhD, FNLA

The William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR
Diplomate, American Board of Clinical Lipidology

DAVID R. NEFF, DO

President, Midwest Lipid Association
Michigan State University
College of Osteopathic Medicine
Associate Clinical Professor
Department of Family & Community Medicine
Ingham Regional Medical Center
Lansing, MI

0
No votes yet

What is the Structure of Lp(a)?

Article By:

PATRICK M. MORIARTY, MD, FNLA

Professor of Medicine
Director of Clinical Pharmacology
University of Kansas Medical Center
Kansas City, KS

MICHAEL B. BOFFA, PhD

Associate Professor
Department of Biochemistry
Schulich School of Medicine & Dentistry
The University of Western Ontario
London, ON

MARLYS KOSCHINSKY, PhD, FNLA

Scientific & Executive Director, Robarts Research Institute
Professor, Department of Physiology & Pharmacology
Schulich School of Medicine & Dentistry
The University of Western Ontario
London, ON

0
No votes yet

Our healthcare organization has designated “population health management” as a core part of our strategy planning and accountability. This is reflected through the implementation of what is defined as the “quadruple aim:”

–providing health care which is affordable, improves the patient experience from the standpoint of quality and satisfaction in terms of outcomes, and also supports the physicians and providers of that healthcare in their life goals and personal quality–

Article By:

KAYE-EILEEN WILLARD, MD, FNLA

Co-Editor, LipidSpin
Medical Director, Lipid Clinic and Physician Advisor
Ascension Wisconsin All Saints
Racine, WI
Diplomate, American Board of Clinical Lipidology

0
No votes yet

Greetings from those of us at the Midwest Lipid Association (MWLA). We all trust that you had an excellent summer as we head into cooler weather and color changes up here in the Midwest and Canada. For those of you who do not know, our Canadian partners who are National Lipid Association (NLA) members are represented through the MWLA Chapter. It’s our pleasure to bring you this issue of LipidSpin.

Article By:

DAVID R. NEFF, DO

President, Midwest Lipid Association
Michigan State University
College of Osteopathic Medicine
Associate Clinical Professor
Department of Family & Community Medicine
Ingham Regional Medical Center
Lansing, MI

0
No votes yet